Japan & Eisai
6 shared events · Importance 3 · Last updated Aug 04, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Japan: Japan's stock market experienced significant volatility, influenced by global factors and domestic economic data.
Eisai: Eisai gained more than 3% on one day, reflecting gains.
Jul 24, 2026 · 37 articles
Business
Japan: Leqembi approved in Japan; subcutaneous formulation application submitted in Nov 2025.
Eisai: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
Business
Japan: Japan is Eisai's home country and an existing market for Leqembi; the India launch has minimal direct impact.
Eisai: Eisai is the primary actor, launching Leqembi in India, which could drive revenue growth and strengthen its position in the Alzheimer's treatment market.
Aug 03, 2026 · 6 articles
International
Eisai: Eisai is expected to announce investments and collaborations in life sciences as part of the broader UK-Japan agreements.
Jun 13, 2026 · 26 articles
Business
Eisai: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Japan and Eisai interact across events, view sentiment trends, and discover connected entities.
Open Dashboard